Which of the following is a characteristic of low molecular weight heparin (LMWH)?

Low molecular weight heparin (LMWH) is characterized by having a longer half-life than unfractionated heparin (UFH). This longer half-life contributes to its convenience and effectiveness in clinical use. LMWH is designed to provide more predictable pharmacokinetics, which allows for less frequent dosing compared to UFH. Patients can be treated with LMWH once or twice daily without the need for frequent monitoring of blood levels or activated partial thromboplastin time (aPTT), which is often necessary with UFH.

The primary mechanism of action of LMWH is to enhance the inhibition of factor Xa, rather than factor Va; this distinction is crucial for understanding their different therapeutic roles. Additionally, LMWH is not used as a fibrinolytic agent, as its primary function is to prevent thrombus formation rather than dissolve existing clots. These characteristics make LMWH a valuable tool in the management of conditions such as venous thromboembolism and in settings like surgical prophylaxis.